CCL27 and breast cancer: As a result, utilizing molecular assays specifically designed for ILC may enhance prognostic accuracy compared to currently available gene expression assays—Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50), intrinsic subtyping and risk of recurrence (ROR) score, Oncotype DX breast recurrence score (RS), MammaPrint and EPclin risk stratification for emerging distant metastasis, Breast Cancer Index (BCI) recurrence prediction and GenomicG (GG) for a better reclassification of breast tumors [60].